TY - JOUR
T1 - Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens
AU - Jacobs, Miriam N.
AU - Colacci, Annamaria
AU - Corvi, Raffaella
AU - Vaccari, Monica
AU - Aguila, M. Cecilia
AU - Corvaro, Marco
AU - Delrue, Nathalie
AU - Desaulniers, Daniel
AU - Ertych, Norman
AU - Jacobs, Abigail
AU - Luijten, Mirjam
AU - Madia, Federica
AU - Nishikawa, Akiyoshi
AU - Ogawa, Kumiko
AU - Ohmori, Kiyomi
AU - Paparella, Martin
AU - Sharma, Anoop Kumar
AU - Vasseur, Paule
PY - 2020
Y1 - 2020
N2 - While regulatory requirements for carcinogenicity testing of chemicals vary according to product sector and regulatory jurisdiction, the standard approach starts with a battery of genotoxicity tests (which include mutagenicity assays). If any of the in vivo genotoxicity tests are positive, a lifetime rodent cancer bioassay may be requested, but under most chemical regulations (except plant protection, biocides, pharmaceuticals), this is rare. The decision to conduct further testing based on genotoxicity test outcomes creates a regulatory gap for the identification of non-genotoxic carcinogens (NGTxC). With the objective of addressing this gap, in 2016, the Organization of Economic Cooperation and Development (OECD) established an expert group to develop an integrated approach to the testing and assessment (IATA) of NGTxC. Through that work, a definition of NGTxC in a regulatory context was agreed. Using the adverse outcome pathway (AOP) concept, various cancer models were developed, and overarching mechanisms and modes of action were identified. After further refining and structuring with respect to the common hallmarks of cancer and knowing that NGTxC act through a large variety of specific mechanisms, with cell proliferation commonly being a unifying element, it became evident that a panel of tests covering multiple biological traits will be needed to populate the IATA. Consequently, in addition to literature and database investigation, the OECD opened a call for relevant assays in 2018 to receive suggestions. Here, we report on the definition of NGTxC, on the development of the overarching NGTxC IATA, and on the development of ranking parameters to evaluate the assays. Ultimately the intent is to select the best scoring assays for integration in an NGTxC IATA to better identify carcinogens and reduce public health hazards.
AB - While regulatory requirements for carcinogenicity testing of chemicals vary according to product sector and regulatory jurisdiction, the standard approach starts with a battery of genotoxicity tests (which include mutagenicity assays). If any of the in vivo genotoxicity tests are positive, a lifetime rodent cancer bioassay may be requested, but under most chemical regulations (except plant protection, biocides, pharmaceuticals), this is rare. The decision to conduct further testing based on genotoxicity test outcomes creates a regulatory gap for the identification of non-genotoxic carcinogens (NGTxC). With the objective of addressing this gap, in 2016, the Organization of Economic Cooperation and Development (OECD) established an expert group to develop an integrated approach to the testing and assessment (IATA) of NGTxC. Through that work, a definition of NGTxC in a regulatory context was agreed. Using the adverse outcome pathway (AOP) concept, various cancer models were developed, and overarching mechanisms and modes of action were identified. After further refining and structuring with respect to the common hallmarks of cancer and knowing that NGTxC act through a large variety of specific mechanisms, with cell proliferation commonly being a unifying element, it became evident that a panel of tests covering multiple biological traits will be needed to populate the IATA. Consequently, in addition to literature and database investigation, the OECD opened a call for relevant assays in 2018 to receive suggestions. Here, we report on the definition of NGTxC, on the development of the overarching NGTxC IATA, and on the development of ranking parameters to evaluate the assays. Ultimately the intent is to select the best scoring assays for integration in an NGTxC IATA to better identify carcinogens and reduce public health hazards.
KW - Cancer hallmarks
KW - Cancer microenvironment
KW - Cancer model
KW - Cancer prevention
KW - Hazard assessment
KW - IATA
KW - Integrated approaches to testing and assessment
KW - Non-genotoxic carcinogenicity
U2 - 10.1007/s00204-020-02784-5
DO - 10.1007/s00204-020-02784-5
M3 - Journal article
C2 - 32594184
AN - SCOPUS:85086873129
SN - 0340-5761
VL - 94
SP - 2899
EP - 2923
JO - Archives of Toxicology
JF - Archives of Toxicology
IS - 8
ER -